Cross-source evidence timeline

Goserelin research timeline

Follow 64 selected, directly cited source records from December 29, 1989 through November 12, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.

64Selected records
17Source years
3Evidence lanes
November 12, 2026Latest source date

Source year

2026

12 records
  1. Clinical trials

    ClinicalTrials.gov record NCT07310420↗

    PeptideScanner retained ClinicalTrials.gov record NCT07310420 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was goserelin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT02115282↗

    PeptideScanner retained ClinicalTrials.gov record NCT02115282 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was goserelin.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT05161195↗

    PeptideScanner retained ClinicalTrials.gov record NCT05161195 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was goserelin.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT02003209↗

    PeptideScanner retained ClinicalTrials.gov record NCT02003209 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was goserelin.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT01723774↗

    PeptideScanner retained ClinicalTrials.gov record NCT01723774 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was goserelin.↗

  6. Literature metadata

    Roles of Goserelin in Gynecological Disorders.↗

    PubMed lists PMID 42226753 in Drug design, development and therapy as Journal Article, Review, with publication-date metadata of 2026-05-27 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT03671330↗

    PeptideScanner retained ClinicalTrials.gov record NCT03671330 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-07-08, and PeptideScanner's reviewed identity mapping was goserelin.↗

  8. Literature metadata

    Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer.↗

    PubMed lists PMID 26131799 in Medicine as Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2015-07 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    Goserelin ('Zoladex')--offering patients more choice in early breast cancer.↗

    PubMed lists PMID 15590321 in European journal of oncology nursing : the official journal of European Oncology Nursing Society as Journal Article, Review, with publication-date metadata of 2004 (year precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    A Phase II trial of Zoladex combined with CEF chemotherapy as neoadjuvant therapy in premenopausal women with hormone-responsive, operable breast cancer.↗

    PubMed lists PMID 21380781 in Medical oncology (Northwood, London, England) as Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2011-03-06 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Literature metadata

    Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.↗

    PubMed lists PMID 22265697 in The Lancet. Oncology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-01-20 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients.↗

    PubMed lists PMID 23184499 in Breast cancer (Tokyo, Japan) as Clinical Trial, Journal Article, with publication-date metadata of 2012-11-25 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2025

6 records
  1. Clinical trials

    ClinicalTrials.gov record NCT03822468↗

    PeptideScanner retained ClinicalTrials.gov record NCT03822468 at 2026-11-15T21:50:32.222Z. Its registry update date was 2025-10-16, and PeptideScanner's reviewed identity mapping was goserelin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT02430480↗

    PeptideScanner retained ClinicalTrials.gov record NCT02430480 at 2026-11-15T21:50:32.222Z. Its registry update date was 2025-07-16, and PeptideScanner's reviewed identity mapping was goserelin.↗

  3. Literature metadata

    [Phase Ⅲ, multicenter, randomized comparative study of LY01005 and Zoladex® for patients with premenopausal breast cancer].↗

    PubMed lists PMID 40268551 in Zhonghua zhong liu za zhi [Chinese journal of oncology] as Journal Article, Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase III, Comparative Study, and 1 more PubMed publication type, with publication-date metadata of 2025-04-23 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT00328614↗

    PeptideScanner retained ClinicalTrials.gov record NCT00328614 at 2026-11-15T21:50:32.222Z. Its registry update date was 2025-05-16, and PeptideScanner's reviewed identity mapping was goserelin.↗

  5. Literature metadata

    Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer.↗

    PubMed lists PMID 21625929 in Breast cancer research and treatment as Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2011-05-29 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU.↗

    PubMed lists PMID 38940667 in Clinical cancer research : an official journal of the American Association for Cancer Research as Journal Article, Clinical Trial, Phase II, Multicenter Study, with publication-date metadata of 2024-08-15 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2024

5 records
  1. Clinical trials

    ClinicalTrials.gov record NCT03839823↗

    PeptideScanner retained ClinicalTrials.gov record NCT03839823 at 2026-11-15T21:50:32.222Z. Its registry update date was 2024-10-09, and PeptideScanner's reviewed identity mapping was goserelin.↗

  2. Literature metadata

    A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer.↗

    PubMed lists PMID 15668708 in British journal of cancer as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2005-02-14 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT03007979↗

    PeptideScanner retained ClinicalTrials.gov record NCT03007979 at 2026-11-15T21:50:32.222Z. Its registry update date was 2024-03-20, and PeptideScanner's reviewed identity mapping was goserelin.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT00295646↗

    PeptideScanner retained ClinicalTrials.gov record NCT00295646 at 2026-11-15T21:50:32.222Z. Its registry update date was 2024-03-15, and PeptideScanner's reviewed identity mapping was goserelin.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT02278120↗

    PeptideScanner retained ClinicalTrials.gov record NCT02278120 at 2026-11-15T21:50:32.222Z. Its registry update date was 2024-03-12, and PeptideScanner's reviewed identity mapping was goserelin.↗

Source year

2023

2 records
  1. Literature metadata

    Erythema nodosum caused by goserelin acetate sustained-release: Case report and literature review.↗

    PubMed lists PMID 37114900 in International journal of rheumatic diseases as Review, Case Reports, Journal Article, with publication-date metadata of 2023-04-28 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT00432172↗

    PeptideScanner retained ClinicalTrials.gov record NCT00432172 at 2026-11-15T21:50:32.222Z. Its registry update date was 2023-04-03, and PeptideScanner's reviewed identity mapping was goserelin.↗

Source year

2022

9 records
  1. Clinical trials

    ClinicalTrials.gov record NCT00004124↗

    PeptideScanner retained ClinicalTrials.gov record NCT00004124 at 2026-11-15T21:50:32.222Z. Its registry update date was 2022-12-30, and PeptideScanner's reviewed identity mapping was goserelin.↗

  2. Regulatory

    Federal Register notice 2022-25210↗

    The Federal Register published notice 2022-25210, attributed to FDA and its parent HHS department, on 2022-11-18. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon and Goserelin.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT00005044↗

    PeptideScanner retained ClinicalTrials.gov record NCT00005044 at 2026-11-15T21:50:32.222Z. Its registry update date was 2022-06-15, and PeptideScanner's reviewed identity mapping was goserelin.↗

  4. Literature metadata

    Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.↗

    PubMed lists PMID 14679153 in Journal of the National Cancer Institute as Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, and 1 more PubMed publication type, with publication-date metadata of 2003-12-17 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.↗

    PubMed lists PMID 20679610 in Journal of clinical oncology : official journal of the American Society of Clinical Oncology as Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010-08-02 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer.↗

    PubMed lists PMID 16222310 in British journal of cancer as Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2005-09-19 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.↗

    PubMed lists PMID 14760369 in British journal of cancer as Clinical Trial, Journal Article, with publication-date metadata of 2004-02-09 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.↗

    PubMed lists PMID 22972694 in Cancer as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-09-12 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT02586675↗

    PeptideScanner retained ClinicalTrials.gov record NCT02586675 at 2026-11-15T21:50:32.222Z. Its registry update date was 2022-01-21, and PeptideScanner's reviewed identity mapping was goserelin.↗

Source year

2021

2 records
  1. Clinical trials

    ClinicalTrials.gov record NCT03096847↗

    PeptideScanner retained ClinicalTrials.gov record NCT03096847 at 2026-11-15T21:50:32.222Z. Its registry update date was 2021-10-11, and PeptideScanner's reviewed identity mapping was goserelin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT02518191↗

    PeptideScanner retained ClinicalTrials.gov record NCT02518191 at 2026-11-15T21:50:32.222Z. Its registry update date was 2021-06-11, and PeptideScanner's reviewed identity mapping was goserelin.↗

Source year

2019

5 records
  1. Literature metadata

    Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study.↗

    PubMed lists PMID 12217302 in European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology as Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2002-08 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT00114114↗

    PeptideScanner retained ClinicalTrials.gov record NCT00114114 at 2026-11-15T21:50:32.222Z. Its registry update date was 2019-10-08, and PeptideScanner's reviewed identity mapping was goserelin.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT00186121↗

    PeptideScanner retained ClinicalTrials.gov record NCT00186121 at 2026-11-15T21:50:32.222Z. Its registry update date was 2019-10-07, and PeptideScanner's reviewed identity mapping was goserelin.↗

  4. Literature metadata

    Goserelin acetate in combination with radiotherapy for prostate cancer.↗

    PubMed lists PMID 17257094 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2007-02 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study.↗

    PubMed lists PMID 12477997 in American journal of clinical oncology as Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 2002-12 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2018

5 records
  1. Clinical trials

    ClinicalTrials.gov record NCT01073865↗

    PeptideScanner retained ClinicalTrials.gov record NCT01073865 at 2026-11-15T21:50:32.222Z. Its registry update date was 2018-12-12, and PeptideScanner's reviewed identity mapping was goserelin.↗

  2. Literature metadata

    Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF).↗

    PubMed lists PMID 14530912 in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA as Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2003-10-03 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women.↗

    PubMed lists PMID 16392882 in Drugs as Journal Article, Review, with publication-date metadata of 2005 (year precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT00283803↗

    PeptideScanner retained ClinicalTrials.gov record NCT00283803 at 2026-11-15T21:50:32.222Z. Its registry update date was 2018-08-07, and PeptideScanner's reviewed identity mapping was goserelin.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT01496131↗

    PeptideScanner retained ClinicalTrials.gov record NCT01496131 at 2026-11-15T21:50:32.222Z. Its registry update date was 2018-03-09, and PeptideScanner's reviewed identity mapping was goserelin.↗

Source year

2016

2 records
  1. Literature metadata

    Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patien…↗

    PubMed lists PMID 12488405 in Journal of clinical oncology : official journal of the American Society of Clinical Oncology as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2002-12-15 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT00586898↗

    PeptideScanner retained ClinicalTrials.gov record NCT00586898 at 2026-11-15T21:50:32.222Z. Its registry update date was 2016-03-25, and PeptideScanner's reviewed identity mapping was goserelin.↗

Source year

2015

2 records
  1. Clinical trials

    ClinicalTrials.gov record NCT00108732↗

    PeptideScanner retained ClinicalTrials.gov record NCT00108732 at 2026-11-15T21:50:32.222Z. Its registry update date was 2015-06-30, and PeptideScanner's reviewed identity mapping was goserelin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT01682642↗

    PeptideScanner retained ClinicalTrials.gov record NCT01682642 at 2026-11-15T21:50:32.222Z. Its registry update date was 2015-03-20, and PeptideScanner's reviewed identity mapping was goserelin.↗

Source year

2014

2 records
  1. Literature metadata

    Goserelin and bicalutamide treatments alter the expression of microRNAs in the prostate.↗

    PubMed lists PMID 22674191 in The Prostate as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-06-05 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT01250717↗

    PeptideScanner retained ClinicalTrials.gov record NCT01250717 at 2026-11-15T21:50:32.222Z. Its registry update date was 2014-02-04, and PeptideScanner's reviewed identity mapping was goserelin.↗

Source year

2013

7 records
  1. Literature metadata

    Treating relapsed epithelial ovarian cancer with luteinizing hormone-releasing agonist (goserelin) after failure of chemotherapy.↗

    PubMed lists PMID 12183859 in The Israel Medical Association journal : IMAJ as Clinical Trial, Journal Article, with publication-date metadata of 2002-08 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    European randomized, multicenter study of goserelin (Zoladex) in the management of mastalgia.↗

    PubMed lists PMID 15592276 in American journal of obstetrics and gynecology as Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Use of goserelin in the treatment of breast cancer.↗

    PubMed lists PMID 16111461 in Expert review of anticancer therapy as Journal Article, Review, with publication-date metadata of 2005-08 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    [Assessment of goserelin treatment in adjuvant therapy for premenopausal patients with breast cancer in Japan-zoladex breast cancer study group trial-B].↗

    PubMed lists PMID 16352931 in Gan to kagaku ryoho. Cancer & chemotherapy as English Abstract, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2005-12 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    [Hysteroresection of submucous myomas after treatment with zoladex].↗

    PubMed lists PMID 16637313 in Akusherstvo i ginekologiia as Clinical Trial, English Abstract, Journal Article, with publication-date metadata of 2006 (year precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93).↗

    PubMed lists PMID 16765589 in European journal of cancer (Oxford, England : 1990) as Clinical Trial, Phase IV, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2006-06-12 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    [Using GnRH-agonists (Zoladex) in the treatment of genital endometriosis].↗

    PubMed lists PMID 16889194 in Akusherstvo i ginekologiia as Clinical Trial, English Abstract, Journal Article, with publication-date metadata of 2006 (year precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2012

1 record
  1. Clinical trials

    ClinicalTrials.gov record NCT00605267↗

    PeptideScanner retained ClinicalTrials.gov record NCT00605267 at 2026-11-15T21:50:32.222Z. Its registry update date was 2012-09-06, and PeptideScanner's reviewed identity mapping was goserelin.↗

Source year

2011

1 record
  1. Clinical trials

    ClinicalTrials.gov record NCT00322348↗

    PeptideScanner retained ClinicalTrials.gov record NCT00322348 at 2026-11-15T21:50:32.222Z. Its registry update date was 2011-01-24, and PeptideScanner's reviewed identity mapping was goserelin.↗

Source year

1997

1 record
  1. Regulatory

    Federal Register notice 97-10911↗

    The Federal Register published notice 97-10911, attributed to FDA and its parent HHS department, on 1997-04-28. Its official title is “Environmental Assessments and Findings of No Significant Impact,” and PeptideScanner's exact reviewed identity mapping connects the document to Goserelin.↗

Source year

1996

1 record
  1. Regulatory

    Drugs@FDA application NDA020578↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 020578 with status AP dated 1996-01-11, and names goserelin acetate among the application record's active ingredients.↗

Source year

1989

1 record
  1. Regulatory

    Drugs@FDA application NDA019726↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 019726 with status AP dated 1989-12-29, and names goserelin acetate among the application record's active ingredients.↗